88338TAA2
Theravance Biopharma, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes YUPELRI (revefenacin), a once-daily nebulized medicine that helps people with COPD breathe more easily, sold in the US with partner Viatris. It grew out of Theravance, Inc., founded in 1996, which split in 2014 into two public companies, with Theravance Biopharma keeping the respiratory drug pipeline. Its name blends "therapy" and "advance"—fitting for a firm built on advancing medicine.
NOTEUnderlying: TBPHCUSIP: 88338TAA2HealthcareUS1 derivative reporter
3.000% Fixed Rate Note
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
